Gasmi Mehdi 4
4 · Adverum Biotechnologies, Inc. · Filed Jun 17, 2020
Insider Transaction Report
Form 4
Gasmi Mehdi
VP, Pharmaceutical Development
Transactions
- Sale
Common Stock
2020-06-15$21.01/sh−5,000$105,042→ 279,442 total - Exercise/Conversion
Common Stock
2020-06-15$4.80/sh+10,000$48,000→ 284,442 total - Sale
Common Stock
2020-06-15$21.93/sh−1,416$31,047→ 278,026 total - Sale
Common Stock
2020-06-15$23.00/sh−3,425$78,787→ 274,601 total - Sale
Common Stock
2020-06-15$23.59/sh−159$3,751→ 274,442 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-06-15−10,000→ 118,000 totalExercise: $4.80Exp: 2026-02-11→ Common Stock (10,000 underlying)
Footnotes (6)
- [F1]Shares sold pursuant to a 10b5-1 plan.
- [F2]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.50 to $21.49. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $21.51 to $22.42. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F4]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $22.55 to $23.39. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F5]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $23.57 to $23.63. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F6]Fully vested and exercisable.